Bond.az White LogoBond.az Black Logo

Morgan Stanley Reiterates Home Depot Rating on Execution

Morgan Stanley reiterates Overweight rating on Home Depot with $420 target, citing solid execution in a growthless housing market.

Luna Torres
ByLuna Torres- Senior Editor
|
0

Morgan Stanley reiterated an Overweight rating and $420 price target on Home Depot (NYSE:HD) after the company's Q1 fiscal 2026 results.

The firm notes Home Depot executes well in a growthless environment. The housing backdrop remains static. Shares trade at $299.81, near the 52-week low of $296.88. The stock is down 12% YTD and 19% over the past year.

Transactions are stable at a high level, possibly impacted by weather in April. The consensus mis-modeled Q1 gross margin, making the quarter complexion in line.

Morgan Stanley sees favorable risk/reward and likes HD as a high-quality discretionary play. The stock does not price in a housing recovery, trading at a 7% discount to the S&P 500 versus its historical 10-15% premium.

Estimates have bottomed; Q1 results do not change the 2026 EPS power view. Maintenance and repair demand should drive modest growth.

In other news, HD's Q1 results met revenue and earnings expectations. Comparable sales rose 0.6% enterprise-wide and 0.4% in the U.S. EBIT margin of 12.3% beat the Street estimate of 12.1%. Truist Securities and TD Cowen reiterated Buy ratings, while Stifel maintained Hold with a lowered price target from $375 to $320.

More News
2026-06-01 12:02
|
743

Legend Biotech Buy Rating Reiterated

H.C. Wainwright reiterated its Buy rating for Legend Biotech with a $50 target. Revenue up 56% over twelve months.

0
2026-06-01 12:01
|
475

Cogent Stock Price Target Raised to $55

Cogent Biosciences PEAK trial: combination therapy shows 45.6% response rate, 16.5 months PFS, FDA accepts NDA. H.C. Wainwright raises price target to $55.

0
2026-06-01 12:00
|
842

H.C. Wainwright Reaffirms Mineralys Buy

H.C. Wainwright reiterated a Buy rating on Mineralys Therapeutics with a $56 price target after positive trial data.

0
2026-06-01 10:33
|
714

Goldman Sachs Upgrades Marriott Vacations Stock

Goldman Sachs upgrades Marriott Vacations stock to Buy, price target $100. Execution potential drives earnings upside.

0
2026-06-01 10:32
|
730

Goldman Sachs Upgrades Travel + Leisure Stock to Buy

Goldman Sachs upgraded Travel + Leisure stock to Buy with a $85 price target. Learn about the company's financials, dividends, and market outlook.

0
2026-06-01 10:32
|
238

Canaccord Initiates Rare Earths Americas with Buy

Canaccord Genuity initiates Rare Earths Americas with a buy rating and $25 target. Stock at $21.85, offering 14% upside potential.

0
2026-06-01 10:30
|
651

BofA Raises Icon Stock Target to $125 on Bookings

BofA Securities raised Icon plc price target to $125, maintains Underperform. Improved booking trends and Q4 results drive revision.

0
2026-06-01 10:03
|
748

RBC Capital: Sprouts faces Kroger risk

RBC Capital keeps Sprouts rating but sees risks from Kroger price cuts. Analysis and outlook on Bond.az.

0
2026-06-01 09:02
|
551

CLSA Rates Chagee Hold on Margins

CLSA initiated Chagee Holdings with Hold rating and $10 target. Bond.az analysis reveals stock may be undervalued. Read more.

0
2026-06-01 08:31
|
594

Barclays Downgrades Sensata Stock on Valuation

Barclays downgrades Sensata stock to Equalweight on valuation concerns, but raises price target to $53. Stock surged 92% in past year.

0
2026-06-01 08:05
|
946

UBS Initiates Veritone Coverage with Neutral

UBS initiated coverage on Veritone with a Neutral rating and $2.50 price target. The AI company is better positioned for growth after transformation.

0
2026-06-01 08:02
|
892

JMP Securities Initiates Microsoft with Outperform on AI Strategy

JMP Securities initiates Microsoft with Market Outperform rating and $550 target on AI strategy. Revenue growth expected to reach 17% in FY2026.

0
...
Morgan Stanley Reiterates Home Depot Rating on Execution | Bond.az